Compare CHT & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CHT | ONC |
|---|---|---|
| Founded | 1996 | 2010 |
| Country | Taiwan | Switzerland |
| Employees | N/A | 12000 |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.8B | 40.6B |
| IPO Year | 2003 | 2015 |
| Metric | CHT | ONC |
|---|---|---|
| Price | $49.91 | $415.95 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 27 |
| Target Price | N/A | ★ $465.00 |
| AVG Volume (30 Days) | 129.3K | ★ 442.0K |
| Earning Date | 11-04-2026 | 11-05-2026 |
| Dividend Yield | ★ 2.55% | N/A |
| EPS Growth | N/A | ★ 140.43 |
| EPS | N/A | ★ 0.56 |
| Revenue | N/A | ★ $238,387,000.00 |
| Revenue This Year | $6.52 | $29.05 |
| Revenue Next Year | $1.44 | $15.06 |
| P/E Ratio | ★ $26.66 | $743.85 |
| Revenue Growth | N/A | ★ 22179.16 |
| 52 Week Low | $39.28 | $253.95 |
| 52 Week High | $50.15 | $424.73 |
| Indicator | CHT | ONC |
|---|---|---|
| Relative Strength Index (RSI) | 67.98 | 67.27 |
| Support Level | $41.92 | $341.67 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.52 | 10.70 |
| MACD | -0.02 | 4.37 |
| Stochastic Oscillator | 82.95 | 88.77 |
Chunghwa Telecom Co Ltd is Taiwan's integrated telecom operator, providing fixed-line, wireless, and Internet and data services. The company's reportable segments are: Consumer Business, Enterprise Business, International Business, and Others. The majority of its revenue comes from the Consumer Business, which focuses on individual and home-centric businesses, such as mobile, fixed broadband, Wi-Fi, IPTV (MOD), and OTT services. The Enterprise business offers IDC, cloud, cybersecurity, 5G, AIoT, data, AI, enterprise digital transformation, and system integration services to businesses, and the International business segment represents services offered to international customers. Geographically, the company generates maximum revenue from its business in Taiwan.
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of Non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up for 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has a global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes with AbbVie and AstraZeneca mainly. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.